Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo

Antiviral Research

Volumn 47, Issue 1, 2000, Pages 41-51

  Kimura, Kazufumi ^a   Mori, Shuichi ^a   Tomita, Kiyoko ^a   Ohno, Kouei ^a   Takahashi, Kazuo ^a   Shigeta, Shiro ^a   Terada, Masaki ^b  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b Nissin Molecular Biology Institute   (United States)

Author keywords

Cell culture infectious dose; NMSO3; RSV infections

Indexed keywords

ANTIVIRUS AGENT; DEXTRAN SULFATE; LIPID; MONOCLONAL ANTIBODY; NMSO 3; RIBAVIRIN; SODIUM [2,2 BIS(DOCOSYLOXYMETHYL)PROPYL 5 ACETOAMIDO 3,5 DIDEOXY 4,7,8,9 TETRA O (SODIUM OXYSULFONYL) D GLYCERO ALPHA D GALACTO 2 NONULOPYRANOSID]ONATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ORTHOMYXOVIRUS; PARAMYXOVIRUS; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DOGS; HELA CELLS; HUMANS; INJECTIONS, INTRAPERITONEAL; LIPIDS; MOLECULAR CONFORMATION; N-ACETYLNEURAMINIC ACID; RATS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RIBAVIRIN; SIGMODONTINAE; VERO CELLS;

EID: 0033892730     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00091-7     Document Type: Article

References (21)

1. Anderson L.J., Hierholzer J.C., Bingham P.G., Stone Y.O. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J. Clin. Microbiol. 22:1985;1050-1052.
2. Barnard D.L., Hill C.L., Gage T., Matheson J.E., Huffman J.H., Sidwell R.W., Otto M.I., Schinazi R.F. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antivir. Res. 34:1997;27-37.
3. De Clercq E. Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections. Int. J. Antimicrob. Agents. 7:1996;193-202.
4. Englund J.A., Sullivan C.J., Jordan M.C., Dehner L.P., Vercellotti G.M., Balfour H. Respiratory syncytial virus infection in immunocompromised adults. Ann. Int. Med. 109:1988;203-208.
5. Harrington R.D., Hooton T.M., Hackman R.C., Storch G.A., Osborne B., Gleaves C.A., Benson A., Meyers J.D. An outbreak of respiratory syncytial virus in bone marrow transplant center. J. Infect. Dis. 165:1992;987-993.
6. Hosoya M., Balzarini J., Shigeta S., De Clercq E. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of viral envelope glycoproteins. Antimicrob. Agents Chemother. 35:1991;2515-2520.
7. Impact RSV Study Group, 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-537.
8. Jairath S., Vargas P.B., Hamlin H.A., Field A.K., Kilkuskie R.E. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antivir. Res. 33:1997;201-213.
9. Kawana F., Shigeta S., Hosoya M., Suzuki H., De Clercq E. Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Antimicrob. Agents Chemother. 31:1987;1225-1230.
10. Lewinsohn D.M., Bowden R.A., Mattson D., Crawford S.W. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob. Agents Chemother. 40:1996;2555-2557.
11. MacDonald N.E., Hall C.B., Suffin S.C., Alexson C., Harris P.J., Manning J.A. Respiratory syncytial virus infection in infants with congenital heart disease. New Engl. J. Med. 307:1982;397-400.
12. Mori S., Watanabe W., Shigeta S. A colorimetric LDH assay for the titration of infectivity and the evaluation of anti-viral activity against ortho- and paramyxoviruses. Tohoku J. Exp. Med. 177:1995;315-325.
13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Meth. 65:1983;55-63.
14. Reed J.L., Muench H. A simple method estimating fifty percent endpoints. Am. J. Hyg. 27:1938;493-497.
15. Shigeta S., Mori S., Baba M., Ito M., Hanzumi K., Nakamura K., Oskitani H., Numazaki Y., Matsuda A., Obara T., Shuto S., DeClercq E. Antiviral activities of ribavirin, 5-ethyl-1-β-D-ribofuranosylimidazole-4-carboxmide, and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob. Agents Chemother. 36:1992;435-439.
16. Shigeta S., Mori S., Baba M., Hosoya M., Mochizuki N., Chiba T., De Clercq E. Inhibitory effect of pyridobenzoazoles on orthomyxo- and paramyxovirus replication in vitro. Antivir. Chem. Chemother. 3:1992;171-177.
17. Smith D.W., Frankel L.R., Mathers L.H., Tang A.T.S., Ariagno R.L., Prober C.G. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infections. New Engl. J. Med. 325:1991;24-29.
18. Watanabe W., Konno K., Ijichi K., Inoue H., Yokota T., Shigeta S. MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents. J. Virol. Meth. 48:1994;257-265.
19. Watanabe W., Sudo K., Sato R., Kajiyashiki T., Konno K., Shigeta S., Yokota T. Novel anti-respiratory syncytial (RS) viral compounds: benzodithiin derivatives. Biochem. Biophys. Res. Commun. 249:1998;922-926.
20. Weltzin R., Traina-Dorge V., Soike K., Zhang J.-Y., Mack P., Soman G., Drabik G., Monath T.P. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J. Infect. Dis. 147:1996;256-261.
21. Wyde P.R., Ambrose M.W., Meyerson L.R., Gilbert B.E. The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parainfluenza type 3 viruses in cotton rats. Antivir. Res. 20:1993;145-154.